Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Stage IIIA Breast Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Stage IIIA Breast Cancer. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2009-018148-45 Sponsor Protocol Number: H3E-EW-JMIP Start Date*: 2010-10-20
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: An exploratory Phase 2 study of Pemetrexed and Cisplatin as Preoperative chemotherapy in the treatment of Stage IIIAN2 nonsquamous non-Small cell lung cancer
    Medical condition: Non Squamous Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029520 LLT
    9.1 10029520 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011739-11 Sponsor Protocol Number: H3E-EW-S128 Start Date*: 2009-08-04
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin with Concurrent Thoracic Radiotherapy, in Patients with Unresectable Locally-Advanced Stage III, Non-Squ...
    Medical condition: Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001170-32 Sponsor Protocol Number: H3E-MC-JMIG Start Date*: 2008-09-05
    Sponsor Name:Eli Lilly and Company limited
    Full Title: Protocol H3E-MC-JMIG Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytoto...
    Medical condition: patients with locally advanced, unresectable/inoperable, Stage III, nonsquamous NSCLC without malignant pleural/pericardial effusion
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) ES (Completed) NL (Completed) BE (Completed) FR (Completed) DE (Completed) GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000662-65 Sponsor Protocol Number: D5164C00001 Start Date*: 2015-08-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, double-blind, randomized, placebo-controlled multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation...
    Medical condition: Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following co...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029517 Non-small cell lung cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029518 Non-small cell lung cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) IT (Completed) DE (Trial now transitioned) HU (Completed) NL (Ongoing) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003912-72 Sponsor Protocol Number: H3E-MC-S103a Start Date*: 2007-10-31
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed alone, and Erlotinib alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Non-Small Cell...
    Medical condition: Patients with histological or cytological diagnosis of nonsquamous NSCLC with locally advanced or metastatic disease. Patients must have failed only one prior chemotherapy regimen and must be consi...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003417-14 Sponsor Protocol Number: GEICAM 2006-10 Start Date*: 2007-09-14
    Sponsor Name:Grupo Español de Investigación en Cáncer de Mama (GEICAM)
    Full Title: Ensayo fase III aleatorizado, multicéntrico, abierto, de grupos paralelos para comparar la eficacia y tolerabilidad de Fulvestrant (Faslodex®) durante tres años en combinación con Anastrozol (Arimi...
    Medical condition: Postmenopausal women with operable breast cancer and positive hormonal receptors who are eligible to be treated with adjuvant hormonotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-018389-22 Sponsor Protocol Number: LAP113957 / SOLTI-1001 Start Date*: 2010-09-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compar...
    Medical condition: patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) AT (Prematurely Ended) FR (Completed) NO (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004950-10 Sponsor Protocol Number: H3E-CR-S111 Start Date*: 2008-01-28
    Sponsor Name:Lilly S.A.
    Full Title: Pemetrexed con suplemento simplificado de folato y dexametasona frente a pemetrexed con suplemento estándar como segunda línea de quimioterapia en pacientes con cáncer de pulmón no microcítico Pe...
    Medical condition: Pacientes con cancer de pulmon no microcitico con enfermedad localmente avanzada o metastásica (estadios IIIA, IIIB o IV).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002662-40 Sponsor Protocol Number: AS.T.R.O.BC01-13 Start Date*: 2013-09-10
    Sponsor Name:AS.T.R.O.
    Full Title: PERtuzumab-trastuzumab plus lEetrozoLe In endocrine Sensitive breast cancer: a phase II neoAdjuvant study
    Medical condition: Stage II-IIIA operable breast cancer, HER2 positive and hormone receptor-positive, previously untreated
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000418-31 Sponsor Protocol Number: IKP275 Start Date*: 2019-04-01
    Sponsor Name:Robert Bosch Gesellschaft für medizinische Forschung mbH
    Full Title: GENOTYPE AND PHENOTYPE GUIDED SUPPLEMENTATION OF TAMOXIFEN STANDARD THERAPY WITH ENDOXIFEN IN BREAST CANCER PATIENTS.
    Medical condition: Patients with ductal carcinoma in situ (DCIS) or early stage breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005173-56 Sponsor Protocol Number: GOG/2007-01 Start Date*: 2008-03-06
    Sponsor Name:Grupo Oncológico Gallego (GOG)
    Full Title: ENSAYO CLÍNICO ABIERTO, NO ALEATORIZADO, EN FASE II, DE TRATAMIENTO SECUENCIAL CON TAXOTERE® (T) SEGUIDO DE MYOCET® Y CICLOFOSFAMIDA (MC), COMO TRATAMIENTO ANTINEOPLASICO PRIMARIO EN PACIENTES CON ...
    Medical condition: Cáncer de mama localizado (estadio II y IIIa).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000251-18 Sponsor Protocol Number: PO4572 Start Date*: 2006-05-12
    Sponsor Name:Dr. Llombart Cussac
    Full Title: Phase II Cardiac Safety trial of liposomal pegillated doxorrubicine in patients with breast cancer with non evidence of disease and previous exposition to Antraciclines. Estudio Fase II de Seguri...
    Medical condition: Non evidence of disease (NED) Breast cancer.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002600-33 Sponsor Protocol Number: IBCSG 34-05/ SWOG 0230 Start Date*: 2007-02-16
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer
    Medical condition: Premenopausal women, Early Stage I, II or IIIA, ER-/ PR- Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-011756-22 Sponsor Protocol Number: ICARO 2 Start Date*: 2009-10-05
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
    Full Title: Reinduction with liposomal anthracyclines and Capecitabine in patients with breast cancer, locally advanced (IIIA-IIIB-IIIC) HER2 negative, not obtaining a pathological complete response (
    Medical condition: Population of female patients suffering from breast cancer in initial clinical stage IIIA, IIIB and IIIC not expressing HER2 and who have not obtained a pathological complete response (defined
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006283 Breast neoplasm malignant female LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002493-13 Sponsor Protocol Number: M16BRC Start Date*: 2016-09-15
    Sponsor Name:NKI-AVL
    Full Title: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy
    Medical condition: High risk breast cancer (stage III), BRCA1-like
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001649-34 Sponsor Protocol Number: CNIO-BR-01-2010/GEICAM/2010-10 Start Date*: 2011-09-19
    Sponsor Name:CNIO - Centro Nacional de Investigaciones Oncológicas
    Full Title: Ensayo clínico de fase I/II, aleatorizado, de paclitaxel neoadyuvante frente a imprimación con BIBF 1120 seguida por BIBF 1120 más paclitaxel en cáncer de mama HER-2 negativo con estudios correlati...
    Medical condition: Pacientes con cáncer de mama localizado (estadios II y IIIA) confirmado histológicamente. Patients histologically confirmed localized breast cancer (stage II and IIIA).
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003029-16 Sponsor Protocol Number: GO29505 Start Date*: 2014-12-01
    Sponsor Name:Genentech, Inc.
    Full Title: A phase II randomized, double-blind study of ipatasertib (GDC-0068), an inhibitor to Akt in combination with paclitaxel as neoadjuvant treatment for patients with early stage triple negative breast...
    Medical condition: Early stage triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001036-22 Sponsor Protocol Number: SOLTI-1114 Start Date*: 2013-10-15
    Sponsor Name:SOLTI
    Full Title: PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in Stage I to IIIA HER2-positive breast cancer
    Medical condition: Untreated invasive breast carcinoma eligible for primary definitive surgery (Stage I-IIIA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-018960-17 Sponsor Protocol Number: TCD11419 Start Date*: 2010-06-16
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: "Estudio de fase II, abierto, aleatorizado para evaluar la eficacia y seguridad de paclitaxel administrado semanalmente como agente único y dos regímenes diferentes de SAR240550 (BSI-201), un inhib...
    Medical condition: Neoadyuvante en pacientes con cáncer de mama triple negativo en estadio II-IIIA (TNBC) _______________________________________________ Neoadjuvant TNBC
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010000-28 Sponsor Protocol Number: BP22572 Start Date*: 2009-08-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An open-label, multi-center study of the safety and tolerability of the combination of Trastuzumab-MCC-DM1 (T-DM1) with docetaxel, and potentially pertuzumab, for treatment for patients with advanc...
    Medical condition: Treatment in patients with advanced, HER2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 07:16:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA